Key facts
- It has raised $580K; the latest was Angel (individual) ($50K) in Jul 2025.
- Notable investors include H7 BioCapital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cellentia
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellentia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellentia
Developer of next-generation patient-derived organoid testing services and translational bioassays designed to model real patient tumor biology. The company offers organoids generated from circulating tumor cells and primary tumors, together with cell-based potency and functional assays, enabling researchers and drug developers access to metastatic disease-relevant models that improve therapeutic decision-making and reduce development risk.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2022
- Employees
- 4
- Website
- cellentiabio.com/
- Ownership
- Privately Held (backing)
Cellentia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellentia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellentia in its N-PORT filings yet. We sweep new filings monthly.